vTv Therapeutics wins FDA Orphan Drug tag for HPPD in sickle cell
vTv Therapeutics has secured FDA Orphan Drug Designation for HPPD (HPP8668), its investigational oral Nrf2/Bach1 modulator being developed for sickle cell disease. The designation, announced on 7 October 2026, confers a package of incentives including seven years of post-approval market exclusivity in the US, fee waivers, and potential tax credits on clinical trial costs, meaningful advantages for a company of vTv's size.
The High Point, North Carolina company is best known for cadisegliatin, a glucokinase activator in Phase 3 for type 1 diabetes that carries FDA Breakthrough Therapy designation. HPPD represents a separate strand of its pipeline, and vTv said the Orphan Drug tag strengthens its hand in seeking a strategic partner for the programme.
Preclinical profile
Preclinical work conducted at Augusta University in the Townes sickle cell disease mouse model showed that HPPD was orally active and well tolerated. The compound induced fetal haemoglobin (HbF) in a time- and dose-dependent manner, with effects described by the company as comparable to or exceeding those of hydroxyurea, the current standard HbF-inducing therapy. HPPD also reduced oxidative stress and red blood cell sickling in the same model. Safety and efficacy have not been established in humans, and no clinical trial start date was announced alongside this release.
Paul Sekhri, chairman, president and chief executive of vTv, said the designation "reinforces both the urgency of the unmet need in this devastating disease and the opportunity to bring forward potential new therapeutic approaches."
Market context
Sickle cell disease affects approximately 100,000 people in the United States, with the burden falling disproportionately on non-Hispanic Black and African American patients. The treatment landscape has expanded considerably in recent years. Vertex Pharmaceuticals and CRISPR Therapeutics received approval in late 2023 for Casgevy, a gene-editing therapy, and bluebird bio's Lyfgenia was approved in the same regulatory cycle. These one-time, high-cost gene therapies address a different patient population from chronic oral agents, leaving a commercially significant gap for patients who are ineligible for or cannot access cell and gene approaches.
Hydroxyurea, despite decades of use, carries tolerability limitations, and a meaningful proportion of patients remain on suboptimal management. GBT Pharmaceuticals' voxelotor was withdrawn from the market in 2024 following a post-marketing trial setback, removing one oral option and reinforcing demand for mechanistically distinct alternatives. HPPD's dual action on HbF induction and oxidative stress, if reproduced in human studies, could position it as a genuinely differentiated oral candidate rather than an incremental improvement on hydroxyurea.
The Nrf2/Bach1 pathway is attracting broader interest beyond sickle cell. A number of academic and spinout groups are exploring Nrf2 modulation across haematological and inflammatory conditions, meaning competitive pressure on the mechanism is likely to intensify as the field matures.
For vTv, the near-term priority is translating the preclinical package into a first-in-human study. Investors will focus on the IND filing timeline, the design of any Phase 1 dose-escalation study, and whether a partnership announcement follows from the partnering discussions Sekhri referenced. The company has not disclosed a development budget for HPPD or confirmed whether it intends to self-fund the clinical programme.